Crestone Pharma

A Groundbreaking Treatment For The Core Symptoms Of Autism

About this Event

Autism impacts millions of people, and its effects can be devastating. Recently it was discovered that alterations in the gut microbiome can precede the development of autism in children.

Crestone Pharmaceutical has developed a highly targeted small molecule antibiotic that has the potential to treat core symptoms of Autism. There are currently no approved drugs for Autism, so any treatment that improves symptoms would be a game changer.

Crestone is ready to begin a Phase 2 trial for Autism with CRS3123, an antibiotic with a narrow-spectrum antibacterial mechanism. This allows it to selectively eliminate C. perfringens, a bacteria that is typically elevated in autistic individuals. It’s also effective on p-cresol, a metabolite of ordinary amino acid tyrosine that has shown to be elevated in autistic individuals in 17 studies.

They are also studying if this same molecule has beneficial effects in treating Parkinson’s Disease. p-Cresol is an irreversible inhibitor of one of the enzymes involved in dopamine homeostasis, and dopamine dysregulation is known to be a contributor to Parkinson’s disease.

Register today to watch our Fireside Chat with Crestone CEO, Nebojsa Janjic, Ph.D, to hear more about the company’s progress and the impact their scientific advancements can have on Autism, leaving lasting, beneficial impact on society.

Video On Demand

– Recorded

December 9

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.